CO-DEVELOPMENT AND COMMERCIALIZATION AGREEMENTCo-Development and Commercialization Agreement • December 3rd, 2012 • RedHill Biopharma Ltd. • Pharmaceutical preparations • London
THIS CO-DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (this “Agreement”) is made and entered into as of August 26, 2010 (the “Effective Date”), by and between IntelGenx Corp., a Canadian corporation (“IntelGenx”), and RedHill Biopharma Ltd., an Israeli company (“RedHill”). IntelGenx and RedHill each may be referred to herein individually as a “Party,” or collectively as the “Parties”.
EX-10.09 16 d538257dex1009.htm CO-DEVELOPMENT AND COMMERCIALIZATION AGREEMENT, OTSUKA PHARMACEUTICAL CO., LTD. CONFIDENTIAL TREATMENT REQUESTED. CERTAIN PORTIONS OF THIS DOCUMENT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND,...Co-Development and Commercialization Agreement • May 5th, 2020 • New York
This Co-Development and Commercialization Agreement (this “Agreement”) is made as of September 4, 2008 (the “Effective Date”), by and between Acucela Inc., a Washington corporation having its principal offices at 21720 23rd Drive SE, Suite 120, Bothell, WA 98021 (“Acucela”), and Otsuka Pharmaceutical Co., Ltd., a Japanese corporation (“Otsuka”) having its principal offices at 2-9 Kanda Tsukasa-cho Chiyoda-ku, Tokyo 101-8535, Japan. Acucela and Otsuka are each referred to herein as a “Party” and collectively as the “Parties.”
Co-Development and Commercialization AgreementCo-Development and Commercialization Agreement • August 5th, 2016 • Advaxis, Inc. • Pharmaceutical preparations • New York
This Co-Development and Commercialization Agreement (this “Agreement”) is made effective as of February 3, 2016 (the “Effective Date”) by and between Advaxis, Inc., a corporation formed under the laws of Delaware (“Advaxis”) having its place of business at 305 College Road East, Princeton, NJ 08540, and Especificos Stendhal SA de CV, a corporation formed under the laws of Mexico City and with headquartered in Av. Camino a Santa Teresa 1040, Mezannine, Jardines en la Montana, Tlalpan, C.P. 14210 Mexico D. F. (“Stendhal”; each of Stendhal and Advaxis are a “Party”, and together, the “Parties”).
November 2016—Horizon Discovery has entered into a co-development and commercialization agreement with Ventana Medical Systems, a member of the Roche group. The agreement covers the development, manufacture, and commercialization of cell-line...Co-Development and Commercialization Agreement • May 15th, 2022
Under the terms of the agreement, Ventana has the option to commission projects from Horizon, whereupon Horizon will develop the applicable cell lines and the associated derivative reference standard materials. Horizon will retain primary responsibility for commercializing the reference standards and will serve as the primary distribution channel to end customers in the tissue diagnostics market. Ventana will hold the option to co-distribute any developed reference standards.
AMENDMENT NO. 2 TO THE CO-DEVELOPMENT AND COMMERCIALIZATION AGREEMENTCo-Development and Commercialization Agreement • February 24th, 2011 • Human Genome Sciences Inc • Biological products, (no disgnostic substances) • Delaware
THIS AMENDMENT NO. 2 TO THE CO-DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (this “Amendment”) is made and entered into as of the 5th day of October 2010 (the “Effective Date”) by and between GLAXO GROUP LIMITED, a company organized under the laws of England and Wales with its principal place of business at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, United Kingdom (“GSK”) and HUMAN GENOME SCIENCES, INC., a Delaware corporation with its principal place of business at 14200 Shady Grove Road, Rockville, Maryland 20850 (“HGS”). GSK and HGS are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and the registrant customarily and actually treats as private and confidential. 3rd Amendment to...Co-Development and Commercialization Agreement • April 16th, 2024 • Ocugen, Inc. • Biological products, (no disgnostic substances)
This 3rd Amendment to Co-Development and Commercialization Agreement (“3rd Amendment”) dated April 11,2023, is made by and between Ocugen, Inc., now with an address at 11 Great Valley Parkway, Malvern, PA 19355 (“Ocugen”), and CanSino Biologics Inc., whose registered office address is at 185 South Ave, TEDA West District, Tianjin, 300457, China (“CanSino”). Ocugen and CanSino are hereinafter referred to individually as a “Party” and collectively as the “Parties.” Capitalized terms that are not defined herein shall have the meaning ascribed to them in the Collaboration Agreement (as defined below).
CONFIDENTIAL PROVISIONS REDACTED AMENDED AND RESTATED CO-DEVELOPMENT AND COMMERCIALIZATION AGREEMENTCo-Development and Commercialization Agreement • March 16th, 2006 • PDL Biopharma, Inc. • Biological products, (no disgnostic substances)
For clarity, Roche shall owe a single payment upon achievement of the event specified in [****], which payment shall satisfy Roche’s obligations with respect to such event both under this [****] and under [****]. If Roche is responsible for achieving an event listed in this [****], [****] of such occurrence. [****].
CO-DEVELOPMENT and COMMERCIALIZATION AGREEMENTCo-Development and Commercialization Agreement • December 23rd, 2009 • Rules-Based Medicine Inc • England
THIS AGREEMENT, effective as of the last date of execution by the parties hereto (hereinafter referred to as the “Effective Date”) is by and between Psynova Neurotech Ltd., having an address at St. John’s Innovation Centre, Cowley Road, Cambridge CB4 0WS, UK (hereinafter referred to as “Psynova”) and Rules Based Medicine, Inc. a corporation having its principal place of business at 3300 Duval Road, Austin, Texas 78759, USA (hereinafter referred to as “RBM”).
CO-DEVELOPMENT AND COMMERCIALIZATION AGREEMENT BETWEEN HUMAN GENOME SCIENCES, INC. AND NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD.Co-Development and Commercialization Agreement • August 9th, 2006 • Human Genome Sciences Inc • In vitro & in vivo diagnostic substances • New York
THIS EXCLUSIVE LICENSE AGREEMENT is made effective as of the 5th day of June 2006 (“Effective Date”) by and between Human Genome Sciences, Inc., a Delaware corporation having its principal place of business at 14200 Shady Grove Road, Rockville, Maryland 20850 (“HGS”), and Novartis International Pharmaceutical Ltd., a Bermuda corporation having its principal place of business at Hurst Holme, 12 Trott Road, Hamilton, HM 11, Bermuda (“NVS”). HGS and NVS are each referred to individually as a “Party” and together as the “Parties.”
Genmab AgreementCo-Development and Commercialization Agreement • April 17th, 2017
In February 2015, Aduro Biotech Europe entered a co-development and commercialization agreement with Genmab to evaluate five DuoBody product candidates targeting immune checkpoints. Genmab and Aduro Biotech Europe will contribute panels of antibodies for the creation of bispecific antibody products using Genmab’s DuoBody platform. If the companies jointly select a product candidate for clinical development, development costs will be shared equally, with each party retaining a 50% share of the product rights. If one of the companies decides not to move a therapeutic candidate forward, the other company is entitled to continue developing the product at predefined licensing terms. The agreement also includes terms which allow the parties to opt out of joint development at key points in each product’s clinical development.
CO-DEVELOPMENT AND COMMERCIALIZATION AGREEMENT BETWEEN HUMAN GENOME SCIENCES, INC. AND GLAXO GROUP LIMITEDCo-Development and Commercialization Agreement • February 26th, 2009 • Human Genome Sciences Inc • In vitro & in vivo diagnostic substances • Delaware
THIS CO-DEVELOPMENT AND COMMERCIALIZATION AGREEMENT is made effective as of the 1st day of August, 2006 (“Effective Date”) by and between Human Genome Sciences, Inc., a Delaware corporation having its principal place of business at 14200 Shady Grove Road, Rockville, Maryland 20850 (“HGS”) and Glaxo Group Limited, a company organized under the laws of England and Wales with its principal place of business at GlaxoWellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, United Kingdom (“GSK”). HGS and GSK shall be referred to herein collectively as “Parties” and individually as a “Party.”
2nd Amendment to the CO-DEVELOPMENT AND COMMERCIALIZATION AGREEMENTCo-Development and Commercialization Agreement • February 28th, 2023 • Ocugen, Inc. • Biological products, (no disgnostic substances)
This 2nd Amendment to the Co-Development and Commercialization Agreement (the “Second Amendment”) is made by and between Ocugen, Inc., now with an address at 11 Great Valley Parkway, Malvern, PA 19355 (“Ocugen”), and CanSino Biologics Inc., whose registered office address is at 185 South Ave, TEDA West District, Tianjin, 300457, China (“CanSino”), and is effective as of the date of the last signature below (the “Second Amendment Effective Date”). Ocugen and CanSino are hereinafter referred to individually as a “Party” and collectively as the “Parties.” Capitalized terms that are not defined herein shall have the meaning ascribed to them in the Collaboration Agreement (as defined below).
CO-DEVELOPMENT AND COMMERCIALIZATION AGREEMENTCo-Development and Commercialization Agreement • November 12th, 2019 • Ocugen, Inc. • Orthopedic, prosthetic & surgical appliances & supplies
This Co-Development and Commercialization Agreement (“Agreement”) dated September 27, 2019 (“Effective Date”) is made by and between:
CO-DEVELOPMENT AND COMMERCIALIZATION AGREEMENTCo-Development and Commercialization Agreement • November 7th, 2008 • Maxygen Inc • Services-commercial physical & biological research • New York
This Co-Development and Commercialization Agreement (this “Agreement”) is entered into as of the 18th day of September, 2008 (“Effective Date”) by and between Astellas Pharma Inc., a Japanese corporation, with its principal place of business at 3-11, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 103-8411 Japan (“Astellas”) and Maxygen, Inc., a Delaware corporation with its principal place of business at 515 Galveston Drive, Redwood City, California, 94063 (“Maxygen”). Astellas and Maxygen are each referred to herein by name or, individually, as a “Party” or, collectively, as the “Parties.”
AMENDMENT No. 1Co-Development and Commercialization Agreement • February 24th, 2011 • Human Genome Sciences Inc • Biological products, (no disgnostic substances)
This Amendment No. 1 (the “Amendment”) is entered into as of the 25th day of November, 2009 (“Amendment No. 1 Date”) by and among Human Genome Sciences, Inc., a Delaware corporation having its principal place of business at 14200 Shady Grove Road, Rockville, Maryland 20850 (“HGS”) and Glaxo Group Limited, a company organized under the laws of England and Wales with its principal place of business at GlaxoWellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, United Kingdom (“GSK”). HGS and GSK are hereinafter individually referred to as a “Party” and collectively as the “Parties.”
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. CO- DEVELOPMENT AND...Co-Development and Commercialization Agreement • May 8th, 2019 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • New York
This CO-DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (this “Agreement”) is entered into and made effective as of February 22, 2019 (the “Effective Date”) by and between Editas Medicine, Inc., a Delaware corporation (“Editas”) and Allergan Sales, LLC, a Delaware limited liability company (“Allergan”). Editas and Allergan are each referred to herein by name or as a “Party” or, collectively, as the “Parties.”
CO-DEVELOPMENT AND COMMERCIALIZATION AGREEMENTCo-Development and Commercialization Agreement • March 15th, 2006 • Maxygen Inc • Services-commercial physical & biological research • Delaware
**** Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
CO-DEVELOPMENT AND COMMERCIALIZATION AGREEMENTCo-Development and Commercialization Agreement • November 5th, 2004 • Protein Design Labs Inc/De • Biological products, (no disgnostic substances)
The attached Development Plan currently identifies the timeline and budget agreed upon by the Parties effective as of [*]. The budget does not include [*], which the Parties have agreed will be reviewed by the JDC for inclusion or exclusion as part of the Development Plan. The Development Plan consists of the following documents:
